Annual EBITDA
-$21.54 M
+$2.53 M+10.51%
December 31, 2023
Summary
- As of February 26, 2025, CASI annual EBITDA is -$21.54 million, with the most recent change of +$2.53 million (+10.51%) on December 31, 2023.
- During the last 3 years, CASI annual EBITDA has risen by +$9.81 million (+31.30%).
- CASI annual EBITDA is now -382.47% below its all-time high of -$4.46 million, reached on December 31, 2010.
Performance
CASI EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$8.09 M
+$1.47 M+15.38%
September 1, 2024
Summary
- As of February 26, 2025, CASI quarterly EBITDA is -$8.09 million, with the most recent change of +$1.47 million (+15.38%) on September 1, 2024.
- Over the past year, CASI quarterly EBITDA has dropped by -$3.32 million (-69.67%).
- CASI quarterly EBITDA is now -808.84% below its all-time high of $1.14 million, reached on December 31, 2010.
Performance
CASI Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$31.62 M
-$2.84 M-9.86%
September 1, 2024
Summary
- As of February 26, 2025, CASI TTM EBITDA is -$31.62 million, with the most recent change of -$2.84 million (-9.86%) on September 1, 2024.
- Over the past year, CASI TTM EBITDA has dropped by -$5.04 million (-18.95%).
- CASI TTM EBITDA is now -1760.18% below its all-time high of -$1.70 million, reached on March 31, 1996.
Performance
CASI TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
CASI EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +10.5% | -69.7% | -18.9% |
| 3 y3 years | +31.3% | -69.7% | -18.9% |
| 5 y5 years | +13.3% | -69.7% | -18.9% |
CASI EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +35.5% | -92.0% | +25.8% | -31.4% | +5.3% |
| 5 y | 5-year | at high | +42.5% | -92.0% | +25.8% | -31.4% | +15.5% |
| alltime | all time | -382.5% | +67.1% | -808.8% | +66.0% | -1760.2% | +54.2% |
CASI Pharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$8.09 M(-15.4%) | -$31.62 M(+9.9%) |
| Jun 2024 | - | -$9.55 M(+3.6%) | -$28.79 M(+0.9%) |
| Mar 2024 | - | -$9.22 M(+93.5%) | -$28.53 M(+7.3%) |
| Dec 2023 | -$21.54 M(-10.5%) | -$4.76 M(-9.2%) | -$26.59 M(+2.1%) |
| Sep 2023 | - | -$5.25 M(-43.6%) | -$26.03 M(-1.3%) |
| Jun 2023 | - | -$9.30 M(+27.9%) | -$26.37 M(+7.7%) |
| Mar 2023 | - | -$7.27 M(+72.7%) | -$24.48 M(+1.7%) |
| Dec 2022 | -$24.07 M(-27.9%) | -$4.21 M(-24.7%) | -$24.07 M(-21.7%) |
| Sep 2022 | - | -$5.59 M(-24.6%) | -$30.75 M(-2.8%) |
| Jun 2022 | - | -$7.41 M(+8.1%) | -$31.63 M(+3.1%) |
| Mar 2022 | - | -$6.86 M(-37.0%) | -$30.68 M(-8.2%) |
| Dec 2021 | -$33.40 M(+6.5%) | -$10.89 M(+68.3%) | -$33.40 M(+4.2%) |
| Sep 2021 | - | -$6.47 M(+0.2%) | -$32.06 M(-2.7%) |
| Jun 2021 | - | -$6.46 M(-32.6%) | -$32.94 M(-1.1%) |
| Mar 2021 | - | -$9.58 M(+0.3%) | -$33.32 M(+6.3%) |
| Dec 2020 | -$31.35 M(-16.2%) | -$9.55 M(+29.9%) | -$31.35 M(-2.3%) |
| Sep 2020 | - | -$7.35 M(+7.6%) | -$32.10 M(-8.4%) |
| Jun 2020 | - | -$6.83 M(-10.3%) | -$35.04 M(-6.0%) |
| Mar 2020 | - | -$7.62 M(-26.0%) | -$37.30 M(-0.4%) |
| Dec 2019 | -$37.43 M(+50.7%) | -$10.29 M(-0.0%) | -$37.43 M(+4.9%) |
| Sep 2019 | - | -$10.30 M(+13.3%) | -$35.68 M(+6.1%) |
| Jun 2019 | - | -$9.09 M(+17.2%) | -$33.64 M(+12.5%) |
| Mar 2019 | - | -$7.75 M(-9.3%) | -$29.90 M(+17.6%) |
| Dec 2018 | -$24.83 M(+133.4%) | -$8.54 M(+3.5%) | -$25.42 M(+16.2%) |
| Sep 2018 | - | -$8.26 M(+54.3%) | -$21.87 M(+43.9%) |
| Jun 2018 | - | -$5.35 M(+63.4%) | -$15.20 M(+24.2%) |
| Mar 2018 | - | -$3.27 M(-34.5%) | -$12.23 M(+15.0%) |
| Dec 2017 | -$10.64 M(+13.7%) | -$5.00 M(+216.5%) | -$10.64 M(+28.3%) |
| Sep 2017 | - | -$1.58 M(-33.8%) | -$8.29 M(-1.1%) |
| Jun 2017 | - | -$2.39 M(+42.2%) | -$8.38 M(-9.5%) |
| Mar 2017 | - | -$1.68 M(-36.6%) | -$9.26 M(-0.9%) |
| Dec 2016 | -$9.35 M(+32.6%) | -$2.65 M(+58.7%) | -$9.35 M(+11.6%) |
| Sep 2016 | - | -$1.67 M(-48.9%) | -$8.38 M(+1.3%) |
| Jun 2016 | - | -$3.27 M(+85.1%) | -$8.27 M(+17.2%) |
| Mar 2016 | - | -$1.77 M(+5.4%) | -$7.06 M(+0.1%) |
| Dec 2015 | -$7.06 M(-73.0%) | -$1.68 M(+7.3%) | -$7.06 M(+1.7%) |
| Sep 2015 | - | -$1.56 M(-23.9%) | -$6.94 M(-74.2%) |
| Jun 2015 | - | -$2.05 M(+16.6%) | -$26.89 M(+1.7%) |
| Mar 2015 | - | -$1.76 M(+13.2%) | -$26.44 M(+1.2%) |
| Dec 2014 | -$26.13 M(+356.5%) | -$1.56 M(-92.8%) | -$26.13 M(+1.0%) |
| Sep 2014 | - | -$21.52 M(+1241.9%) | -$25.87 M(+346.7%) |
| Jun 2014 | - | -$1.60 M(+11.0%) | -$5.79 M(-4.0%) |
| Mar 2014 | - | -$1.44 M(+10.8%) | -$6.04 M(+5.5%) |
| Dec 2013 | -$5.72 M(+27.6%) | -$1.30 M(-9.3%) | -$5.72 M(+39.9%) |
| Sep 2013 | - | -$1.44 M(-22.1%) | -$4.09 M(+6.7%) |
| Jun 2013 | - | -$1.85 M(+63.3%) | -$3.83 M(+1.6%) |
| Mar 2013 | - | -$1.13 M(-444.2%) | -$3.77 M(-15.8%) |
| Dec 2012 | -$4.48 M(-0.8%) | $328.80 K(-127.8%) | -$4.48 M(+18.2%) |
| Sep 2012 | - | -$1.18 M(-33.9%) | -$3.79 M(-1.8%) |
| Jun 2012 | - | -$1.79 M(-2.9%) | -$3.86 M(+3.7%) |
| Mar 2012 | - | -$1.84 M(-280.9%) | -$3.72 M(-17.6%) |
| Dec 2011 | -$4.52 M(+1.3%) | $1.02 M(-181.4%) | -$4.52 M(+2.8%) |
| Sep 2011 | - | -$1.25 M(-24.2%) | -$4.40 M(-14.0%) |
| Jun 2011 | - | -$1.65 M(-37.5%) | -$5.11 M(-2.2%) |
| Mar 2011 | - | -$2.64 M(-331.4%) | -$5.23 M(+17.1%) |
| Dec 2010 | -$4.46 M | $1.14 M(-158.0%) | -$4.46 M(-35.8%) |
| Sep 2010 | - | -$1.97 M(+11.6%) | -$6.95 M(+52.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2010 | - | -$1.76 M(-6.0%) | -$4.55 M(-16.2%) |
| Mar 2010 | - | -$1.88 M(+39.1%) | -$5.42 M(-18.1%) |
| Dec 2009 | -$6.63 M(-66.9%) | -$1.35 M(-406.9%) | -$6.63 M(+0.0%) |
| Sep 2009 | - | $439.30 K(-116.6%) | -$6.62 M(-34.2%) |
| Jun 2009 | - | -$2.64 M(-14.2%) | -$10.07 M(-31.3%) |
| Mar 2009 | - | -$3.08 M(+128.7%) | -$14.66 M(-25.8%) |
| Dec 2008 | -$20.04 M(-15.6%) | -$1.35 M(-55.3%) | -$19.75 M(-10.9%) |
| Sep 2008 | - | -$3.01 M(-58.4%) | -$22.16 M(-1.3%) |
| Jun 2008 | - | -$7.22 M(-11.6%) | -$22.44 M(-5.2%) |
| Mar 2008 | - | -$8.17 M(+117.7%) | -$23.67 M(-0.3%) |
| Dec 2007 | -$23.73 M(+7.0%) | -$3.75 M(+13.9%) | -$23.73 M(-9.1%) |
| Sep 2007 | - | -$3.30 M(-61.0%) | -$26.10 M(-2.7%) |
| Jun 2007 | - | -$8.45 M(+2.7%) | -$26.82 M(+9.7%) |
| Mar 2007 | - | -$8.23 M(+34.4%) | -$24.46 M(+11.7%) |
| Dec 2006 | -$22.17 M(+29.1%) | -$6.12 M(+52.4%) | -$21.89 M(+20.0%) |
| Sep 2006 | - | -$4.02 M(-34.0%) | -$18.24 M(-2.8%) |
| Jun 2006 | - | -$6.09 M(+7.5%) | -$18.77 M(+9.6%) |
| Mar 2006 | - | -$5.66 M(+128.8%) | -$17.13 M(+1.0%) |
| Dec 2005 | -$17.17 M(+8.6%) | -$2.47 M(-45.6%) | -$16.96 M(-4.8%) |
| Sep 2005 | - | -$4.55 M(+2.3%) | -$17.81 M(+5.9%) |
| Jun 2005 | - | -$4.45 M(-18.9%) | -$16.83 M(+2.1%) |
| Mar 2005 | - | -$5.49 M(+64.8%) | -$16.49 M(+4.3%) |
| Dec 2004 | -$15.81 M(-15.8%) | -$3.33 M(-6.6%) | -$15.81 M(-14.5%) |
| Sep 2004 | - | -$3.56 M(-13.3%) | -$18.48 M(-3.8%) |
| Jun 2004 | - | -$4.11 M(-14.4%) | -$19.21 M(-4.2%) |
| Mar 2004 | - | -$4.80 M(-20.0%) | -$20.05 M(+7.6%) |
| Dec 2003 | -$18.77 M(-55.9%) | -$6.01 M(+40.1%) | -$18.64 M(-0.8%) |
| Sep 2003 | - | -$4.29 M(-13.4%) | -$18.78 M(-27.2%) |
| Jun 2003 | - | -$4.95 M(+46.1%) | -$25.81 M(-18.6%) |
| Mar 2003 | - | -$3.39 M(-44.9%) | -$31.72 M(-25.5%) |
| Dec 2002 | -$42.56 M(-35.0%) | -$6.15 M(-45.6%) | -$42.56 M(-29.3%) |
| Sep 2002 | - | -$11.31 M(+4.1%) | -$60.20 M(-7.5%) |
| Jun 2002 | - | -$10.87 M(-23.6%) | -$65.08 M(-5.7%) |
| Mar 2002 | - | -$14.22 M(-40.2%) | -$69.04 M(+5.5%) |
| Dec 2001 | -$65.44 M(+31.8%) | -$23.80 M(+47.1%) | -$65.44 M(+18.0%) |
| Sep 2001 | - | -$16.19 M(+9.2%) | -$55.45 M(+8.8%) |
| Jun 2001 | - | -$14.82 M(+39.6%) | -$50.98 M(+3.1%) |
| Mar 2001 | - | -$10.62 M(-23.1%) | -$49.46 M(-0.4%) |
| Dec 2000 | -$49.64 M(+32.1%) | -$13.82 M(+18.0%) | -$49.64 M(-2.5%) |
| Sep 2000 | - | -$11.72 M(-12.0%) | -$50.90 M(+9.8%) |
| Jun 2000 | - | -$13.31 M(+23.2%) | -$46.35 M(+12.7%) |
| Mar 2000 | - | -$10.80 M(-28.4%) | -$41.13 M(+9.3%) |
| Dec 1999 | -$37.58 M(+150.5%) | -$15.08 M(+110.7%) | -$37.63 M(+36.1%) |
| Sep 1999 | - | -$7.16 M(-11.6%) | -$27.65 M(+11.1%) |
| Jun 1999 | - | -$8.10 M(+10.9%) | -$24.89 M(+31.7%) |
| Mar 1999 | - | -$7.30 M(+43.1%) | -$18.90 M(+26.0%) |
| Dec 1998 | -$15.00 M(+70.5%) | -$5.10 M(+15.9%) | -$15.00 M(+21.0%) |
| Sep 1998 | - | -$4.40 M(+109.5%) | -$12.40 M(+19.2%) |
| Jun 1998 | - | -$2.10 M(-38.2%) | -$10.40 M(+3.0%) |
| Mar 1998 | - | -$3.40 M(+36.0%) | -$10.10 M(+17.4%) |
| Dec 1997 | -$8.80 M(+41.9%) | -$2.50 M(+4.2%) | -$8.60 M(+6.2%) |
| Sep 1997 | - | -$2.40 M(+33.3%) | -$8.10 M(+6.6%) |
| Jun 1997 | - | -$1.80 M(-5.3%) | -$7.60 M(+20.6%) |
| Mar 1997 | - | -$1.90 M(-5.0%) | -$6.30 M(+3.3%) |
| Dec 1996 | -$6.20 M | -$2.00 M(+5.3%) | -$6.10 M(+48.8%) |
| Sep 1996 | - | -$1.90 M(+280.0%) | -$4.10 M(+86.4%) |
| Jun 1996 | - | -$500.00 K(-70.6%) | -$2.20 M(+29.4%) |
| Mar 1996 | - | -$1.70 M | -$1.70 M |
FAQ
- What is CASI Pharmaceuticals annual EBITDA?
- What is the all time high annual EBITDA for CASI Pharmaceuticals?
- What is CASI Pharmaceuticals annual EBITDA year-on-year change?
- What is CASI Pharmaceuticals quarterly EBITDA?
- What is the all time high quarterly EBITDA for CASI Pharmaceuticals?
- What is CASI Pharmaceuticals quarterly EBITDA year-on-year change?
- What is CASI Pharmaceuticals TTM EBITDA?
- What is the all time high TTM EBITDA for CASI Pharmaceuticals?
- What is CASI Pharmaceuticals TTM EBITDA year-on-year change?
What is CASI Pharmaceuticals annual EBITDA?
The current annual EBITDA of CASI is -$21.54 M
What is the all time high annual EBITDA for CASI Pharmaceuticals?
CASI Pharmaceuticals all-time high annual EBITDA is -$4.46 M
What is CASI Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, CASI annual EBITDA has changed by +$2.53 M (+10.51%)
What is CASI Pharmaceuticals quarterly EBITDA?
The current quarterly EBITDA of CASI is -$8.09 M
What is the all time high quarterly EBITDA for CASI Pharmaceuticals?
CASI Pharmaceuticals all-time high quarterly EBITDA is $1.14 M
What is CASI Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, CASI quarterly EBITDA has changed by -$3.32 M (-69.67%)
What is CASI Pharmaceuticals TTM EBITDA?
The current TTM EBITDA of CASI is -$31.62 M
What is the all time high TTM EBITDA for CASI Pharmaceuticals?
CASI Pharmaceuticals all-time high TTM EBITDA is -$1.70 M
What is CASI Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, CASI TTM EBITDA has changed by -$5.04 M (-18.95%)